What is this study trying to find out about ARDS in pediatric burn patients?

This study aims to see if certain blood count ratios, called Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios, can predict the development of acute respiratory distress syndrome (ARDS) in children with severe burns. The research helps understand how these blood markers relate to lung complications after burns. It is led by Ain Shams University and involves careful observation of children in the burn ICU.

Who may be eligible for this pediatric burn clinical trial?

Children aged 1 to 12 years with severe thermal or scald burns covering 20% to 40% of their body, admitted within 24 hours of injury, may be eligible. Both boys and girls can participate. Children with chronic liver, kidney, or lung diseases, anemia, or other serious medical conditions are excluded. Please review eligibility criteria for more details.

Is there any cost to participate in this pediatric burn clinical trial?

Study-related care, including all tests and monitoring, is provided at no cost. Personal travel and other expenses may vary and are not guaranteed to be covered. Participants can expect their care during the trial to be provided without charge, but any extra costs outside the study are their responsibility.

Actively Recruiting

Age: 1Year - 12Years

All Genders

ID07414056

Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Predictors of ARDS in Pediatric Burn Patients A Prospective Observational Study

Led by Ain Shams University · Updated on 2026-03-02

Participants Needed

Research Sites

26 weeks

Total Duration

AI-Summary

What this Trial Is About

This research aims to evaluate how Neutrophil-to-Lymphocyte Ratio NLR and Platelet-to-Lymphocyte Ratio PLR can predict acute respiratory distress syndrome ARDS in children with severe burns. The study focuses on pediatric patients aged 1 to 12 years admitted within 24 hours of burn injury, assessing if these blood count ratios help foresee ARDS development. It is a prospective observational cohort study conducted in a burn intensive care unit. The study involves monitoring blood counts to calculate NLR and PLR at admission and on days 1, 3, 5, and 7. Clinical information such as burn severity, inhalation injury, and respiratory support will be recorded. Researchers will follow patients closely for signs of ARDS using established pediatric criteria and record ventilation needs and duration. The goal is to find predictive blood marker cut-off values and compare these ratios with standard clinical predictors. Participants will undergo regular blood tests and respiratory evaluations throughout their stay. Data collected include patient characteristics, burn severity scores, respiratory status, and outcomes like mechanical ventilation use, ICU length of stay, and mortality. The primary outcome is to assess how well admission NLR and PLR predict ARDS within 30 days. Secondary outcomes include analyzing changes in these ratios over time and their relation to clinical severity and outcomes.

CONDITIONS

Brief Title

Turning Ratios Into Prognosis: Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Powerful Predictors of ARDS in Pediatric Burn Patients: A Prospective Evaluation

Who Can Participate

Age: 1Year - 12Years

All Genders

Eligibility Criteria

You may qualify if you...

Age between 1 and 12 years
Presenting within 24 hours of burn injury
Severe burns covering 20% to 40% of total body surface area
Thermal burns or scald injuries
Both male and female patients

You will not qualify if you...

Refusal to participate in the trial
Age younger than 1 year or older than 12 years
Admission delayed more than 24 hours after injury
Burns covering less than 20% or more than 40% of total body surface area
Non-thermal burns
Chronic liver or kidney disease, anemia
Preexisting chronic lung diseases such as cystic fibrosis or severe bronchopulmonary dysplasia
Inflammatory conditions like inflammatory bowel disease
Immunocompromised status, autoimmune diseases, or ongoing treatment with immunosuppressants, corticosteroids, or chemotherapy
Known malignancies or blood disorders affecting white blood cells or platelets
Previous malnutrition
Immunosuppressive therapy before admission such as chronic steroid use

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here